•Innovative Aerosystems announced the acquisition of Aydin Displays, a developer of rugged display technologies for defense, for $24.5 million in cash.
•Celldex reported that topline results from its Phase 2 study of barzolvolimab in prurigo nodularis did not meet the primary or key secondary endpoints.